Bispecific IgG monoclonal antibody that binds CD20 on B cells and CD3 on T cells, redirecting and activating T cells to kill CD20+ malignant B cells.
Humanized bispecific IgG that binds CD20 on B cells and CD3 on T cells, physically linking T cells to CD20+ malignant B cells to trigger T‑cell activation, immune synapse formation, and cytotoxic killing of the target B cells.
Mosunetuzumab bridges CD20 on B cells to CD3 on T cells, forming an immune synapse and activating T cells to kill the CD20+ cells via perforin/granzyme-mediated cytotoxicity (and related apoptotic pathways).
Chimeric IgG1 monoclonal antibody targeting EGFR; binds the extracellular domain to block ligand binding and receptor dimerization, inhibiting downstream MAPK/ERK and PI3K/AKT signaling and tumor cell proliferation. The IgG1 Fc also engages Fcγ receptors to mediate ADCC against EGFR-expressing cells.
Cetuximab binds EGFR on target cells and its IgG1 Fc engages Fc gamma receptor–bearing effector cells (e.g., NK cells) to mediate ADCC, killing EGFR-expressing cells; complement-dependent cytotoxicity may also occur.
Investigational intravenous immunotherapy; specific target/mechanism not specified in the registry (administered every 2 weeks, the day after toripalimab).
SMET12 is a bispecific anti-EGFR/CD3 T-cell engager antibody that binds EGFR on tumor cells and CD3 on T cells, crosslinking and activating cytotoxic T lymphocytes to redirect them to EGFR-expressing tumor cells and induce targeted T-cell-mediated killing.
Bispecific anti-EGFR/CD3 T-cell engager crosslinks T cells to EGFR+ cells, activating cytotoxic T lymphocytes to kill target cells via perforin/granzyme-mediated lysis (and related T-cell cytotoxic pathways).
Afucosylated human IgG1 monoclonal antibody (AMG 451/KHK4083) targeting OX40 (CD134); blocks OX40–OX40L costimulatory signaling and promotes ADCC-mediated depletion of OX40+ activated/effector-memory T cells to reduce T cell–driven airway inflammation and type 2 cytokines (IL-4, IL-5, IL-13). Administered subcutaneously.
Afucosylated human IgG1 monoclonal antibody targeting OX40 (CD134) that blocks OX40–OX40L costimulatory signaling and enhances ADCC to deplete OX40+ activated/effector-memory T cells, reducing type 2 cytokines (IL-4, IL-5, IL-13) and T cell–driven inflammation.
The afucosylated IgG1 antibody binds OX40 on activated T cells and engages FcγRIIIa on NK cells/other effectors to trigger ADCC, leading to lysis/apoptosis of OX40+ cells.
Autologous ex vivo–expanded tumor-infiltrating lymphocyte (TIL) cell therapy enriched for tumor-reactive T cells; mediates anti-tumor activity via TCR recognition and cytotoxic mechanisms (perforin/granzyme) with cytokine secretion.
Autologous ex vivo–expanded tumor-infiltrating T cells that retain native TCRs to recognize patient-specific tumor antigens and mediate anti-tumor effects via cytotoxic granule release (perforin/granzyme) and cytokine secretion, leading to direct tumor-cell killing and immune amplification.
Infused autologous TILs recognize the neoantigen peptide–HLA class I complex via their native TCRs and directly kill target cells through perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis), with supportive cytokine effects.